Who are Erdos capsule's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): DEXTROAMPHETAMINE, bupropion immediate release (IR), Duloxetine (Cymbalta), Effexor® (Venlafaxine), sibutramine+ microcrystalline cellulose, Drug treatment with Cymbalta.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/erdos-capsule.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Erdos capsule — Competitive Intelligence Brief

Erdos capsule (Erdos capsule) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: norepinephrine reuptake inhibitor. Area: Psychiatry.

marketed norepinephrine reuptake inhibitor norepinephrine transporter Psychiatry Small molecule Live · refreshed every 30 min

Target snapshot

Erdos capsule (Erdos capsule) — Kwang-Ha Yoo. Erdos capsule works by inhibiting the reuptake of norepinephrine, a neurotransmitter that plays a key role in attention and arousal.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Erdos capsule TARGET	Erdos capsule	Kwang-Ha Yoo	marketed	norepinephrine reuptake inhibitor	norepinephrine transporter
DEXTROAMPHETAMINE	DEXTROAMPHETAMINE		marketed	Central nervous system stimulant	Dopamine transporter (DAT), Norepinephrine transporter (NET)	1955-01-01
bupropion immediate release (IR)	bupropion-immediate-release-ir	Pfizer	marketed	Norepinephrine-dopamine reuptake inhibitor	Dopamine transporter, Norepinephrine transporter
Duloxetine (Cymbalta)	Duloxetine (Cymbalta)	New York State Psychiatric Institute	marketed	Serotonin-norepinephrine reuptake inhibitor (SNRI)	Serotonin transporter (SERT); Norepinephrine transporter (NET)
Effexor® (Venlafaxine)	Effexor® (Venlafaxine)	Wyeth is now a wholly owned subsidiary of Pfizer	marketed	Serotonin-norepinephrine reuptake inhibitor (SNRI)	Serotonin transporter (SERT); Norepinephrine transporter (NET)
sibutramine+ microcrystalline cellulose	sibutramine+ microcrystalline cellulose	Promomed, LLC	marketed	Sympathomimetic amine; appetite suppressant	Norepinephrine transporter (NET), serotonin transporter (SERT), dopamine transporter (DAT)
Drug treatment with Cymbalta	Drug treatment with Cymbalta	Jefferson Clinic, P.C.	marketed	Serotonin-norepinephrine reuptake inhibitor (SNRI)	Serotonin and norepinephrine transporters

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2033-10-24 — DEXTROAMPHETAMINE · 9456993 · Formulation · US
2033-10-24 — DEXTROAMPHETAMINE · 9474722 · Formulation · US
2042-01-06 — DEXTROAMPHETAMINE · 11559501 · Formulation · US

Sponsor landscape (norepinephrine reuptake inhibitor class)

CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · 1 drug in this class
Kwang-Ha Yoo · 1 drug in this class
Sanofi · 1 drug in this class
Shanghai Huilun Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Erdos capsule — Competitive Intelligence Brief. https://druglandscape.com/ci/erdos-capsule. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab